PCSK9 Inhibitor [EPC]

99505 reported adverse events

Drugs of this class: ALIROCUMAB EVOLOCUMAB

These side effects are most commonly reported by patients taking drugs of the PCSK9 Inhibitor [EPC] class:

# Side effect Count
0 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 9063
1 INJECTION SITE PAIN 7727
2 ACCIDENTAL EXPOSURE TO PRODUCT 6340
3 MYALGIA 5476
4 DRUG DOSE OMISSION 5255
5 BACK PAIN 4719
6 INJECTION SITE BRUISING 3941
7 ARTHRALGIA 3730
8 FATIGUE 3628
9 RHINORRHOEA 3413
See all common reactions for PCSK9 Inhibitor [EPC]

Drugs of the PCSK9 Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 LOW DENSITY LIPOPROTEIN DECREASED 577 0.6158
1 ADMINISTRATION SITE INDENTATION 12 0.3750
2 TYPE IIA HYPERLIPIDAEMIA 45 0.3435
3 BLOOD CHOLESTEROL DECREASED 379 0.2936
4 LOW DENSITY LIPOPROTEIN ABNORMAL 100 0.2915
5 INCORRECT DISPOSAL OF PRODUCT 233 0.2495
6 LIPOPROTEIN (A) INCREASED 27 0.2160
7 LOW DENSITY LIPOPROTEIN INCREASED 921 0.1754
8 ACCIDENTAL EXPOSURE TO PRODUCT 6340 0.1496
9 DEVICE DISPENSING ERROR 54 0.1436
See all enriched reactions for PCSK9 Inhibitor [EPC]